We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05269667
Recruitment Status : Recruiting
First Posted : March 8, 2022
Last Update Posted : January 17, 2023
Sponsor:
Collaborator:
Chugai Pharmaceutical Co.
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab (RTX) (or its biosimilar)

Condition or disease Intervention/treatment Phase
Neuromyelitis Optica Spectrum Disorder NMOSD Drug: Satralizumab 120 mg Phase 4

Detailed Description:

Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) are severe demyelinating inflammatory autoimmune neurological disorders. The estimated global pooled prevalence of NMOSD is 1.82 per 100 000 people (Etemadifar et al. 2015). The disorder is characterized by inflammatory lesions in the optic nerve, spinal cord, brainstem, and cerebrum; and clinically by optic neuritis (ON) and/or transverse myelitis causing potentially severe motor and sensory impairment, bladder dysfunction, vision loss, pain, and other debilitating symptoms (Wingerchuk et al. 2015). Recovery is variable, and inflammatory attacks often result in permanent disability. Untreated, the risks of severe disability or death are substantial (Jarius et al. 2014).

NMOSD is radiologically and prognostically distinct from multiple sclerosis (MS), and has a pathophysiology unresponsive to typical MS treatment (Weinshenker 2007; Oh, and Levy et al. 2012).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SAkuraBonsai: Clinical, Imaging And Biomarker Open-Label Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Actual Study Start Date : August 2, 2022
Estimated Primary Completion Date : May 29, 2026
Estimated Study Completion Date : January 15, 2027


Arm Intervention/treatment
Experimental: Cohort 1: treatment-naïve NMOSD patients
Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
Drug: Satralizumab 120 mg
Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).

Experimental: Cohort 2: NMOSD patients who are inadequate responders to previous treatment with RTX
Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
Drug: Satralizumab 120 mg
Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).




Primary Outcome Measures :
  1. Proportion of relapse-free patients [ Time Frame: Up to Week 96 ]
  2. Annualized relapse rate (ARR) [ Time Frame: Up to Week 96 ]
  3. Time to first relapse (TFR) [ Time Frame: Up to Week 96 ]
  4. Mean change from baseline in Expanded Disability Status Scale (EDSS) score over the course of the study [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
    The Expanded Disability Status Scale ranges from 0 to 10 in 0.5 unit increments. Higher results represent higher levels of disability.

  5. Time to onset of confirmed disability progression (CDP) sustained for at least 12 weeks and 24 weeks [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
  6. Change from baseline in the Symbol Digital Modalities Test (SDMT) over the course of the study [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
  7. Change in high-contrast (100%) and lowcontrast (2.5%) visual acuity using appropriate high-and low-contrast letter acuity (LCLA) charts over the course of the study [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
  8. Proportion of participants hospitalized due to relapse [ Time Frame: Up to Week 96 ]
  9. Proportion of participants using corticosteroids due to relapse [ Time Frame: Up to Week 96 ]
  10. Proportion of participants in need of rescue therapy due to relapse [ Time Frame: Up to Week 96 ]
  11. Proportion of participants in need of plasma exchange due to relapse [ Time Frame: Up to Week 96 ]
  12. Proportion of participants with disability (measured by Expanded Disability Status Scale EDSS) due to relapse [ Time Frame: Up to Week 96 ]

Secondary Outcome Measures :
  1. Count, volume and regional distribution of T2-weighted fluid-attenuated inversion-recovery (FLAIR) hyperintense lesions [ Time Frame: Up to Week 96 ]
    Including new and enlarging lesions of the cerebrum, optic nerves, optic chiasm, area postrema, brainstem and cerebellum; Fazekas scoring

  2. Global and regional brain volume loss including basal ganglia, cerebellum and upper cervical spinal cord. [ Time Frame: At Screening, Weeks 48 and 96 ]
  3. New and persisting short T1 inversion recovery (STIR)/Proton Density (PD) hyperintense lesions and T1-weighted contrast enhancement [ Time Frame: Up to Week 96 ]
  4. Quantitative T1 mapping (magnetizationprepared rapid gradient echo sequence [MP2RAGE]) [ Time Frame: Up to Week 96 ]
  5. Quantitative diffusion/diffusion tensor imaging (DTI) [ Time Frame: Up to Week 96 ]
  6. Change in the retinal nerve fiber layer (RNFL) thickness [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
  7. Change in the ganglion cell plus inner plexiform (GCIP) layer thickness [ Time Frame: Baseline (Day -28 to Day -1) to Week 96 ]
  8. Incidence and severity of adverse events (AEs), serious AEs (SAEs) and AEs of special interest (AESIs) [ Time Frame: Up to Week 96 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Age 18 to 74 years, inclusive, at the time of informed consent
  • Have a diagnosis of AQP4 antibody seropositive NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria
  • For women of childbearing potential: agreement to either remain abstinent (refrain from heterosexual intercourse) or to use reliable means of contraception (physical barrier [patient or partner] in conjunction with a spermicidal product, contraceptive pill, patch, injectables, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug Cohort 1 (treatment-naïve NMOSD patients)
  • Confirmation of NMOSD diagnosis with AQP4+ antibodies
  • Have clinical evidence of at least 1 documented attack or relapse (including first attack) in the last year prior to screening
  • Naive to maintenance therapy (disease-modifying therapy [DMT] or immunosuppressive therapy [IST]) Cohort 2 (NMOSD patients with inadequate response to RTX [or its biosimilar])
  • Confirmation of NMOSD diagnosis and AQP4+ antibodies in the disease history of the patient
  • Have a length of disease duration from first symptom of ≤5 years
  • History of ongoing treatment with RTX (or its biosimilar) (at least 2 infusions) for NMOSD with a maximum duration of 6 months since last administration prior to enrolment in the study
  • Ongoing disease activity after last RTX (or its biosimilar) infusion i.e., relapse and/or any new inflammatory event, confirmed by magnetic resonance imaging (MRI) or ophthalmological assessment

Exclusion criteria Exclusion criteria for both the cohorts

  • Inability to complete an MRI
  • Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of satralizumab
  • Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline
  • Evidence of other demyelinating disease, including MS or progressive multifocal leukoencephalopathy (PML)
  • Evidence of serious uncontrolled concomitant diseases that may preclude patient participation
  • Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection or other infection (excluding fungal infections of nail beds or caries dentium) at baseline
  • Infection requiring hospitalization or treatment with intravenous (IV) anti-infective agents within 4 weeks prior to baseline visit
  • Evidence of chronic active hepatitis B
  • Evidence of active tuberculosis (TB)
  • History or laboratory evidence of coagulation disorders
  • Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline
  • Presence or history of malignancy
  • History of drug or alcohol abuse within 1 year prior to baseline
  • History of diverticulitis that, in the Investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation
  • History of severe allergic reaction to a biologic agent
  • Active suicidal ideation within 6 months prior to screening, or history of suicide attempt within 3 years prior to screening
  • Treatment with any investigational agent within 6 months prior to baseline or 5 drug elimination half-lives of the investigational agent (whichever is longer) Cohort 1 (treatment-naïve NMOSD patients)
  • Any previous treatment with IL-6 inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation, stem-cell therapy, or bone marrow transplantation
  • Any previous treatment with eculizumab, belimumab, natalizumab, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, siponimod, or ozanimod
  • Any previous treatment with anti-CD4, cladribine or mitoxantrone
  • Any previous treatment with B-cell depleting agents
  • Any previous treatment with immunosuppressants Cohort 2 (NMOSD patients with inadequate response to RTX)
  • Discontinued RTX (or biosimilar) treatment due to any other reason than inadequate response to treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05269667


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: MN42928, https://forpatients.roche.com/ 888-662-6728 (U.S.) global-roche-genentech-trials@gene.com

Locations
Layout table for location information
United States, Colorado
University Of Colorado Recruiting
Aurora, Colorado, United States, 80045
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, Texas
University of Texas Southwestern Medical Center Withdrawn
Dallas, Texas, United States, 75390
France
Hopital La Pitie Salpetriere Recruiting
Paris, France, 75013
CHU Strasbourg Hôpital Hautepierre Recruiting
Strasbourg, France, 67098
CHU de Toulouse - Hôpital Purpan Recruiting
Toulouse, France, 31059
Italy
Irccs A.O.U.San Martino Ist; Dinogmi Recruiting
Genova, Liguria, Italy, 16132
Japan
Chiba University Hospital Recruiting
Chiba, Japan, 260-8677
Korea, Republic of
National Cancer Center Recruiting
Goyang-si, Korea, Republic of, 10408
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Turkey
Hacettepe University Medical Faculty; Neurology Recruiting
Ankara, Turkey, 06100
Ondokuz Mayis University School of Medicine; Neurology Recruiting
Samsun, Turkey, 55139
Sponsors and Collaborators
Hoffmann-La Roche
Chugai Pharmaceutical Co.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT05269667    
Other Study ID Numbers: MN42928
2021-001088-26 ( EudraCT Number )
First Posted: March 8, 2022    Key Record Dates
Last Update Posted: January 17, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromyelitis Optica
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Eye Diseases
Autoimmune Diseases
Immune System Diseases